BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine

Haematologica. 2016 Nov;101(11):e445-e448. doi: 10.3324/haematol.2016.142521. Epub 2016 Jul 21.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimetabolites, Antineoplastic / pharmacology
  • Azacitidine / administration & dosage
  • Azacitidine / analogs & derivatives*
  • Azacitidine / pharmacology
  • Bone Marrow / chemistry
  • Case-Control Studies
  • Cell Line
  • DNA Methylation
  • Decitabine
  • Humans
  • Leukemia, Myeloid, Acute / mortality
  • Leukemia, Myeloid, Acute / pathology*
  • Membrane Proteins / analysis*
  • Myelodysplastic Syndromes / mortality
  • Myelodysplastic Syndromes / pathology*
  • Proto-Oncogene Proteins / analysis*
  • Survival Analysis
  • Treatment Outcome
  • Tumor Suppressor Proteins / analysis*

Substances

  • Antimetabolites, Antineoplastic
  • BNIP3L protein, human
  • Membrane Proteins
  • Proto-Oncogene Proteins
  • Tumor Suppressor Proteins
  • Decitabine
  • Azacitidine